Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease

Treatment Guidelines for Mother and Baby

At a Glance

Treatment for congenital toxoplasmosis uses spiramycin to prevent the parasite from crossing the placenta. If the baby is already infected, a triple regimen of pyrimethamine, sulfadiazine, and folinic acid is prescribed during pregnancy and must continue for a full 12 months after birth.

When a pregnancy is affected by toxoplasmosis, the medical focus turns toward treatment as a primary tool for protecting the baby. Depending on whether the parasite has reached the baby, the standard of care involves two different approaches. These treatments are designed to either block the parasite’s path or stop its growth if it has already crossed the placenta [1][2].

Preventing Transmission: Spiramycin

If your tests show a recent infection but there is no proof yet that the baby is infected, doctors typically discuss using spiramycin.

  • The Goal: To act as a “shield.” Spiramycin concentrates in the placenta to help prevent the parasite from passing from the mother to the baby [1][3].
  • The Timing: It is most effective when started as soon as possible after a maternal infection is suspected [4].
  • The Impact: Studies have shown that early use of spiramycin can significantly reduce the risk of the baby being born with severe symptoms or eye issues [2][5].

Treating Fetal Infection: The Triple Regimen

If an amniocentesis (PCR test) or ultrasound suggests the baby has been infected, the medical team usually transitions to a more potent combination of medications known as the triple regimen [2][6]. You will take these pills by mouth, and the medication will pass through your placenta to reach and treat the baby before birth [1]. This regimen consists of:

  1. Pyrimethamine: An antiparasitic drug that stops the parasite from reproducing by blocking its access to certain nutrients [7]. Note: This medication often needs to be sourced through a specialty pharmacy rather than your local drug store. Your care team will help coordinate this [3].
  2. Sulfadiazine: An antibiotic that works alongside pyrimethamine to further inhibit the parasite’s growth [8].
  3. Folinic Acid (Leucovorin): A specialized form of B-vitamin that is essential for this treatment [9].

Why Folinic Acid is Critical

You may be familiar with folic acid from prenatal vitamins, but folinic acid is different. Pyrimethamine works so well because it starves the parasite of folate. However, this can also affect the baby’s own bone marrow, where blood cells are made [7].

  • The “Rescue” Agent: Folinic acid acts as a “rescue” agent. Human cells can use it to stay healthy even while the drug is starving the parasite [10][11].
  • Monitoring: Because this treatment can lower blood counts, babies (and sometimes mothers) on this regimen require regular blood tests—often weekly—to check for bone marrow suppression (a drop in white blood cells or platelets) [12][8].

Postnatal Treatment for the Infant

After birth, if a baby is confirmed to have congenital toxoplasmosis, the triple regimen (Pyrimethamine, Sulfadiazine, and Folinic Acid) is typically continued [13].

  • Duration: The standard course of treatment for the baby lasts for a full 12 months [14][15].
  • Crucial Note for Asymptomatic Babies: Even if your baby is born looking perfectly healthy and shows absolutely zero symptoms at birth, completing the full 12 months of this medication is critical [14]. Stopping the medication early because the baby “seems fine” or because the weekly blood tests are stressful leaves the child vulnerable to developing late-onset blindness or permanent brain damage later in life [16][17].

Throughout this process, your medical team—which may include an infectious disease specialist and a perinatologist—will monitor the dosages closely to ensure they are safe and effective for both you and your baby [18].

Common questions in this guide

What is the difference between spiramycin and the triple regimen for congenital toxoplasmosis?
Spiramycin is used to prevent the toxoplasmosis parasite from crossing the placenta when a mother is infected, acting as a shield for the baby. The triple regimen is a stronger combination of medications used to treat the baby if the parasite has already crossed the placenta.
Why do I need to take folinic acid with my toxoplasmosis medication?
The main anti-parasite medication works by starving the parasite of folate, which can also affect the baby's bone marrow. Folinic acid acts as a rescue agent that protects healthy human cells without stopping the medication from fighting the infection.
How long will my baby need to take medication for congenital toxoplasmosis after birth?
Babies born with congenital toxoplasmosis typically need to take the triple regimen medications for a full 12 months after birth. It is crucial to complete this entire year of treatment, even if the baby appears perfectly healthy and has no symptoms.
Why do babies treated for toxoplasmosis need weekly blood tests?
The medications used to treat congenital toxoplasmosis can sometimes cause bone marrow suppression, leading to a drop in white blood cells or platelets. Regular blood tests allow the medical team to monitor these levels and ensure the treatment remains safe for the baby.
Can I stop my baby's toxoplasmosis treatment early if they have no symptoms?
No, you should never stop the medication early. Even if your baby is born looking perfectly healthy, completing the full 12-month course is essential to prevent them from developing late-onset blindness or permanent brain damage later in life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the goal of my current medication to prevent the parasite from crossing the placenta or to treat an active infection in the baby?
  2. 2.If we switch to the pyrimethamine and sulfadiazine combination, how often will the baby need blood tests to monitor their bone marrow?
  3. 3.What is the exact dose of folinic acid required, and why is it important that I don't use regular 'folic acid' supplements instead?
  4. 4.How long do you expect the baby will need to stay on these medications after they are born?
  5. 5.What are the specific 'red flag' side effects (like certain types of rashes or lethargy) I should watch for at home?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Congenital Toxoplasmosis: The State of the Art.

    Bollani L, Auriti C, Achille C, et al.

    Frontiers in pediatrics 2022; (10()):894573 doi:10.3389/fped.2022.894573.

    PMID: 35874584
  2. 2

    A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies.

    Montoya JG, Laessig K, Fazeli MS, et al.

    European journal of medical research 2021; (26(1)):143 doi:10.1186/s40001-021-00606-7.

    PMID: 34895348
  3. 3

    The prevention of congenital toxoplasmosis using a combination of Spiramycin and Cotrimoxazole: The long-time experience of a tertiary referral centre.

    De Santis M, Tartaglia S, Apicella M, et al.

    Tropical medicine & international health : TM & IH 2024; (29(8)):697-705 doi:10.1111/tmi.14021.

    PMID: 38842439
  4. 4

    Congenital toxoplasmosis: Clinical features, outcomes, treatment, and prevention.

    Singh S

    Tropical parasitology 2016; (6(2)):113-122 doi:10.4103/2229-5070.190813.

    PMID: 27722099
  5. 5

    [Effect of antenatal spiramycin treatment on the frequency of retinochoroiditis due to congenital toxoplasmosis in a Colombian cohort].

    Zuluaga LM, Hernández JC, Castaño CF, Donado JH

    Biomedica : revista del Instituto Nacional de Salud 2017; (37(0)):86-91 doi:10.7705/biomedica.v37i2.2818.

    PMID: 28527270
  6. 6

    Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus?

    Prasil P, Sleha R, Kacerovsky M, Bostik P

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2023; (36(1)):2215377 doi:10.1080/14767058.2023.2215377.

    PMID: 37217458
  7. 7

    Adverse Reactions in Antifolate-Treated Toxoplasmic Retinochoroiditis.

    Borkowski PK, Brydak-Godowska J, Basiak W, et al.

    Advances in experimental medicine and biology 2018; (1108()):37-48 doi:10.1007/5584_2018_262.

    PMID: 30191431
  8. 8

    [Toxoplasmosis in pregnancy: Practical Management].

    Mandelbrot L, Kieffer F, Wallon M, et al.

    Gynecologie, obstetrique, fertilite & senologie 2021; (49(10)):782-791 doi:10.1016/j.gofs.2021.03.003.

    PMID: 33677120
  9. 9

    Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

    Dunay IR, Gajurel K, Dhakal R, et al.

    Clinical microbiology reviews 2018; (31(4)) doi:10.1128/CMR.00057-17.

    PMID: 30209035
  10. 10

    Navigating methotrexate toxicity: Examining the therapeutic roles of folinic acid and glucarpidase.

    Chan BS, Bosco AA, Buckley NA

    British journal of clinical pharmacology 2025; (91(3)):628-635 doi:10.1111/bcp.16096.

    PMID: 38889902
  11. 11

    Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder.

    Frye RE, Rossignol DA, Scahill L, et al.

    Seminars in pediatric neurology 2020; (35()):100835 doi:10.1016/j.spen.2020.100835.

    PMID: 32892962
  12. 12

    High Frequency of Bone Marrow Depression During Congenital Toxoplasmosis Therapy in a Cohort of Children Identified by Neonatal Screening in Minas Gerais, Brazil.

    Carellos EVM, de Andrade JQ, Romanelli RMC, et al.

    The Pediatric infectious disease journal 2017; (36(12)):1169-1176 doi:10.1097/INF.0000000000001561.

    PMID: 28151845
  13. 13

    Anti-Toxoplasma Effects of Dracocephalum Polychaetum Essential Oil.

    Khamesipour F, Pourmohammad A, Jafarian-Dehkordi M

    Interdisciplinary perspectives on infectious diseases 2022; (2022()):6091834 doi:10.1155/2022/6091834.

    PMID: 35879954
  14. 14

    Ocular Outcome of Brazilian Patients With Congenital Toxoplasmosis.

    Lago EG, Endres MM, Scheeren MFDC, Fiori HH

    The Pediatric infectious disease journal 2021; (40(1)):e21-e27 doi:10.1097/INF.0000000000002931.

    PMID: 33060522
  15. 15

    Diagnosis of Congenital Toxoplasmosis: Challenges and Management Outcomes.

    Losa A, Carvalho I, Sousa B, et al.

    Cureus 2024; (16(1)):e52971 doi:10.7759/cureus.52971.

    PMID: 38406029
  16. 16

    Toxoplasmosis: A Timeless Challenge for Pregnancy.

    Damar Çakırca T, Can İN, Deniz M, et al.

    Tropical medicine and infectious disease 2023; (8(1)) doi:10.3390/tropicalmed8010063.

    PMID: 36668970
  17. 17

    The effectiveness of congenital toxoplasmosis treatment in minimizing hearing loss: A systematic review.

    Silva Santos RM, Liboredo R, da Silva AS, et al.

    Science progress 2025; (108(2)):368504251320834 doi:10.1177/00368504251320834.

    PMID: 40443220
  18. 18

    Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.

    Ben-Harari RR, Goodwin E, Casoy J

    Drugs in R&D 2017; (17(4)):523-544 doi:10.1007/s40268-017-0206-8.

    PMID: 28879584

This page provides educational information on treatments for congenital toxoplasmosis. Always consult your maternal-fetal medicine specialist or pediatrician for personalized medical advice and medication management.

Get notified when new evidence is published on Congenital toxoplasmosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.